ADC Therapeutics S.A.

ADCT | NYSE

Price Alert Chart Builder DCF Calculator

$1.12

+$0.07 (+6.67%)

At close: Sep 21, 2026, 4:00 PM ET

$1.07

-$0.05 (-4.63%)

After-hours: Sep 21, 2026, 6:09 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+6.67%

(1D)

Rating

Updated: Aug 24, 2026

23.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $142.45M

1D Range

1.08 1.13

52W Range

0.78 4.98

Valuation (TTM)

PE -1.70

PB -0.62

EV/EBITDA -3.89

Valuation (NTM)

Forward PE N/A

Forward PEG 0.15

Price Target $3.50

Cash Flow

FCF Yield -71.8%

SBC Adj. FCF Yield -82.4%

SBC Impact -14.8%

Margins

Gross Margin 88.8%

Operating Margin -125.8%

FCF Margin -129.9%

Growth (CAGR)

Revenue 3Y | 5Y -24.7% | 83.8%

Dil EPS 3Y | 5Y 59.3% | 22.4%

FCF 3Y | 5Y 18.1% | 14.1%

Returns

ROA -34.7%

ROE 44.6%

ROIC -49.5%

Financial Health

Net Debt

$198M

Current Ratio 3.03

Interest Coverage -1.90

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its ...

Sector Healthcare

Industry Biotechnology

Employees 191

IPO Date May 17, 2020

Website www.adctherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 10, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$3.50

Upside

+212.50%

Buy (1)

Hold (2)

Sell (0)

Analyst Details ➞